LY294002

Catalog No.S1105 Synonyms: SF 1101, NSC 697286

For research use only.

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

LY294002 Chemical Structure

CAS No. 154447-36-6

Selleck's LY294002 has been cited by 1483 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Other PI3K Products

Biological Activity

Description LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
Targets
CK2 [5]
(Cell-free assay)
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
DNA-PK [6]
(Cell-free)
98 nM 0.5 μM 0.57 μM 0.97 μM 1.4 μM
In vitro

LY294002 is not exclusively selective for the PI3Ks, and could in fact act on other lipid kinases and additional apparently unrelated proteins. LY294002 is shown to inhibit not only mTOR and DNA-PK, but also other protein kinases, such as CK2 (casein kinase 2) and Pim-1[5]. LY294002 inactivates Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis. LY294002 demonstrates a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser473). [2]LY294002 induces marked nuclear pyknosis and diminished cytoplasmic volume in the tumor cells. Thus, LY294002 markedly inhibits ovarian cancer cell proliferation in vitro. LY294002 induces specific G1 arrest in cell growth, leading to almost complete inhibition of melanoma cell proliferation and partial inhibition of MG-63 (osteosarcoma cell line) proliferation. The effect of LY294002 on cell cycle progression may provide insights into a possible link between the PI3K activation pathway and cancer cell cycle regulation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 cells NGC3N|NHfW6ldHnvckBie3OjeR?= NF[1UIZKdmirYnn0bY9vKG:oIFjpd{11[WepZXSgZo93cW6nIGDJN2sh\XiycnXzd4VlKGmwIGPmPUBk\WyuczygTWM2OD1zMDFOwG0v MlftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB7OUizOVEoRjFyOUm4N|UyRC:jPh?=
HeLa cells MnHkRolv\GmwZzDh[oZqdmm2eTDhd5NigQ>? MXnCbY5lcW6pIHHm[olvcXS7IH\vdkBRUTNva3nuZZNmKGm|b3zheIVlKG[{b32gTIVN[SClZXzsd{whU2l;NjFOwG0> M1K2V|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFcxLz5zNU[1PFg4ODxxYU6=
HeLa cells NV3mR2cxTnWwY4Tpc44h[XO|YYm= NE\vd4dKdmirYnn0bY9vKG:oIH3UU3IheHKxdHXpckBqe2:uYYTl[EBnem:vIFjlUIEh[2WubIOsJGlEPTB;Mj61JO69VS5? MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZ3OEi3NEc,OTV4NUi4O|A9N2F-
HeLa (human carcinoma) cells. M3;Xb2Z2dmO2aX;uJIF{e2G7 MXXJckB3cXS{bzDpcohq[mm2aX;uJI9nKESQQT3k[ZBmdmSnboSgdJJwfGWrbjDrbY5ie2VqRF7BMXBMMSCocn;tJGhmVGFiKHj1cYFvKGOjcnPpco9u[SliY3XscJMtKEmFNUC9NU41KM7:TT6= NYnKfZlPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW2OVg5PzBpPkG1OlU5QDdyPD;hQi=>
human PC3 cells NYDOcWhoWHKxbHnm[ZJifGmxbjDhd5NigQ>? MlT0NlUh|ryP MnzsNVIxKGh? MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyCjdDCyOUB2VSCjZoTldkAyOjBiaILzJIJ6KE2WVDDhd5NigSC{ZXzheIl3\SC2bzDEUXNQ MnnOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ4OECxOVkoRjF4NkiwNVU6RC:jPh?=
human BJ cells NVyxbmpYTnWwY4Tpc44h[XO|YYm= NFvERY8zPSEQvF2= MVGyJIg> MkTZRYN1cX[jdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejNyODDpckBRTEeILYP0bY12dGG2ZXSgd4VzfW1ic4ThdpZm\CCqdX3hckBDUiClZXzsd{BifCB{NTD1UUB1emWjdHXkJFIhcHK|IHLl[o9z\SCSRFfGJINp[WyuZX7n[UBjgSCrbX31co9jdG:2dHnu[y=> MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd4N{C4OUc,OTZ5NkewPFU9N2F-
human BJ cells MoPsSpVv[3Srb36gZZN{[Xl? M{e0VFI2KM7:TR?= MVuyJIg> NF7ScXBKdmirYnn0bY9vKG:oIGDJN2she2mpbnHsbY5oKGmwIGDES2Yue3SrbYXsZZRm\CC|ZYL1cUB{fGG{dnXkJIh2dWGwIFLKJINmdGy|IITyZY5{\mWldHXkJJdqfGhicHzhd41q\CCHR1\QM3BJKGSxbXHpckBw\iCDa4SgZZN{\XO|ZXSgZZMhe3WycILld5Nqd25ib3[gVGguTUeIUDDy[YRqe3S{aXL1eIlwdiC2bzDwcIF{dWFibXXtZpJidmViYYSgNlUhfU1idILlZZRm\CB{IHjyd{Bj\W[xcnWgVGRITiClaHHscIVv\2ViYomgZ49v\m:lYXygcYlkem:|Y3;wfS=> MnPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5NkewPFUoRjF4N{[3NFg2RC:jPh?=
mouse mast cells NGfwWmNHfW6ldHnvckBie3OjeR?= Mk\lNlAh|ryP MVXJcohq[mm2aX;uJI9nKFOFRj3pcoR2[2WmIGDLRk9Cc3RicHjvd5Bpd3K7bHH0bY9vKGmwIH3veZNmKG2jc4SgZ4VtdHNiYYSgNlAh|ryP NV36WVZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3PFk4PDJpPkG2O|g6PzR{PD;hQi=>
THP1 cells NYLZTYN7TnWwY4Tpc44h[XO|YYm= NXPoUphQUW6qaXLpeIlwdiCxZjDNR3AyNWmwZIXj[YQh[2inbX;0ZZhqeyCxZjDUTHAyKGOnbHzzMEBKSzVyPUO3JO69VS5? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd6OUe0Nkc,OTZ5OEm3OFI9N2F-
mouse Raw264 macrophage NGD0UJNHfW6ldHnvckBie3OjeR?= M4XQTmlvcGmkaYTpc44hd2ZiQ{XhMY1m\GmjdHXkJHBMSi:Da4SgdIhwe3Cqb4L5cIF1cW:wIHnuJI1wfXOnIGLhe|I3PCCvYXPyc5Bp[WenLDDJR|UxRTFyIN88UU4> M1yxVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{i5O|QzLz5zNke4PVc1OjxxYU6=
THP1 cells NIrrbI9HfW6ldHnvckBie3OjeR?= NXjWTHg3UW6qaXLpeIlwdiCxZjDNR3AyNWmwZIXj[YQhWEuEL1HreEBxcG:|cHjvdplt[XSrb36gbY4hXEiSMTDj[YxteyxiSVO1NF0yNjZ3IN88UU4> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd6OUe0Nkc,OTZ5OEm3OFI9N2F-
THP1 cells MmH1SpVv[3Srb36gZZN{[Xl? MVvJcohq[mm2aX;uJI9nKFOFRkGtbY5lfWOnZDDQT2IwSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDUTHAyKGOnbHzzMEBKSzVyPUGuNFEh|ryPLh?= NULlVnk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3PFk4PDJpPkG2O|g6PzR{PD;hQi=>
human A375 cells MXTQdo9tcW[ncnH0bY9vKGG|c3H5 NVy5eGpSPDZiaB?= NVLJPWlMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IES2JIhzeyxiSVO1NF05NjRizszNMi=> NVrTUXpIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUewOFkzPDhpPkG3NFQ6OjR6PD;hQi=>
HeLa cells NXHjc|hsTnWwY4Tpc44h[XO|YYm= MoLmTY5pcWKrdHnvckBw\iCDWD23OVA{KGKrbnTpcochfG9icnXjc41jcW6jboSgVIxsOyCneIDy[ZN{\WRiaX6gTIVN[SClZXzsd{BjgSCZZYP0[ZJvKGKub4SsJGlEPT1|IN88UU4> NWjySnhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexN|UzPDhpPkG3NVM2OjR6PD;hQi=>
human SW480 cells MlW2SpVv[3Srb36gZZN{[Xl? M4i0OFIxKM7:TR?= NHPuWmUzPCCq M332b2Rm[3KnYYPlJIlvKHO3co\peolvKGW6cILld5Nqd25iaX6gbJVu[W5iU2e0PFAh[2WubIOgZZQhOjBidV2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4SgZY5idHm|aYO= M3;lOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEeyPVYzLz5zN{S3Nlk3OjxxYU6=
human A375 cells MUXQdo9tcW[ncnH0bY9vKGG|c3H5 MnjxTY5pcWKrdHnvckBw\iC|ZYL1cU1qdmS3Y3XkJJBzd2yrZnXyZZRqd25ib3[gbJVu[W5iQUO3OUBk\WyuczygTWM2OD16LkSg{txONg>? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZyMUezPUc,OTd4MEG3N|k9N2F-
human A2780 cells NFO0cmpCeG:ydH;zbZMh[XO|YYm= MW[yJO69VQ>? NXyyfJRLOTJiaB?= M4SyOWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gZ4l{eGyjdHnuMZJme2m|dHHueEBpfW2jbjDBNlc5OCClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDa4SgcIV3\WxiYYSgNkB2VSCjZoTldkAyOiCqcoOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqey5? NIXiU|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[4OFAyQCd-MUe2PFQxOTh:L3G+
human H4 cells M4HScGZ2dmO2aX;uJIF{e2G7 MUmyJIg> MXvE[YNz\WG|ZTDpckBHYV[HLWLGVEshfmW|aXPs[UBqdnSnboPpeJkheGW{IHPlcIwhcW5iaIXtZY4hUDRiY3XscJMh[W[2ZYKgNkBpenNicnXsZZRqfmVidH:gZ49vfHKxbB?= NIPOdnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOECyOFU5PCd-MUiwNlQ2QDR:L3G+
Sf9 cells MXvGeY5kfGmxbjDhd5NigQ>? Mk\ZTY5pcWKrdHnvckBw\iCFS{Kg[ZhxemW|c3XkJIlvKFOoOTDj[YxteyxiSVO1NF03NjlizszNMi=> NFT6TXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOyNVcyPid-MUizNlE4OTZ:L3G+
rat RBL2H3 cells MlzBSpVv[3Srb36gZZN{[Xl? NIrPU|NKdmirYnn0bY9vKG:oIFGyN|E5Py2rbnT1Z4VlKGSnZ4LhcpVt[XSrb36gbY4hemG2IGLCUFJJOyClZXzsdy=> MnXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|Mki3NVYoRjF6M{K4O|E3RC:jPh?=
human U87MG cells NHzrcG5HfW6ldHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKEeVS{OtZoV1[SCrbjDoeY1idiCXOEfNS{Bk\WyuczDifUBGVEmVQTygTWM2OD16LkGg{txONg>? Mk[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|NEW2NFkoRjF6M{S1OlA6RC:jPh?=
human H460 cells MoXQSpVv[3Srb36gZZN{[Xl? NHXJdo0{OCEQvF2= M1nC[mlvcGmkaYTpc44hd2ZiUFmzT{BqdiCqdX3hckBJPDZyIHPlcIx{KGG|c3Xzd4VlKGG|IFHreEBxcG:|cHjvdplt[XSrb36gZZQhW2W{IES3N{B2eCC2bzCzNEB2VQ>? MkKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3MEG2NFEoRjF6NUCxOlAyRC:jPh?=
human U251HRE cells NEHqflhHfW6ldHnvckBie3OjeR?= MWXJcohq[mm2aX;uJI9nKGi7cH;4bYEucW6mdXPl[EBJUUZzIHHjeIl3[XSrb36gbY4hcHWvYX6gWVI2OUiURTDj[YxteyCkeTDj[YxtKGKjc3XkJJJmeG:{dHXyJIdmdmViYYPzZZk> NVKwWpdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1NFE3ODFpPkG4OVAyPjBzPD;hQi=>
human 184B5 cells M{nKWWN6fG:2b4jpZ:Kh[XO|YYm= M{\FOGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFE5PEJ3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1|OT6zO{DPxE1w MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
human MDA-MB-468 cells NVHo[oEzS3m2b4TvfIlkyqCjc4PhfS=> NVP1PGJ[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BjgSCVUlKgZZN{[XluIFnDOVA:OTBwNDFOwG0v M2DvRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MDA-MB-468 cells MkLzR5l1d3SxeHnjxsBie3OjeR?= Mn7vR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDpckBxemW|ZX7j[UBw\iBzMDD1UUBkcGyxcn;xeYlv\SCkeTDTVmIh[XO|YYmsJGdKPTB;OD6yJO69VS5? M4HPUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
MDA-MB-231 cells MlPTR5l1d3SxeHnjxsBie3OjeR?= MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHL5JHNTSiCjc4PhfUwhT0l3ME22MlcyKM7:TT6= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
human MDA-MB-468 cells M3v5cmN6fG:2b4jpZ:Kh[XO|YYm= MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHnuJJBz\XOnbnPlJI9nKDJyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3Ojef-8kEBKSzVyPUSuO|Yh|ryPLh?= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
human MDA-MB-231 cells NYrrfldpS3m2b4TvfIlkyqCjc4PhfS=> MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHnuJJBz\XOnbnPlJI9nKDFyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3OjeTygS2k2OD12LkO1JO69VS5? NWjkRVlpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MDA-MB-231 cells MkjmR5l1d3SxeHnjxsBie3OjeR?= MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHnuJJBz\XOnbnPlJI9nKDJyIN88UUBkcGyxcn;xeYlv\SCkeTDTVmIh[XO|YYmsJGdKRTNwM{Kg{txONg>? M3;VZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MCF7 cells MojnR5l1d3SxeHnjxsBie3OjeR?= Ml3CR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BjgSCVUlKgZZN{[XluIFfJQVMvOTZizszNMi=> NHSzUFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
human MCF7 cells NETFXFZEgXSxdH;4bYPDqGG|c3H5 NYrBV282S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCrbjDwdoV{\W6lZTDv[kAyOCC3TTDjbIxwem:zdXnu[UBjgSCVUlKgZZN{[XluIFfJOVA:Oy5yODFOwG0v NVPiSGx6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MCF7 cells M2PqSWN6fG:2b4jpZ:Kh[XO|YYm= M2HidWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMhcW5icILld4Vv[2Vib3[gNlAh|ryPIHPocI9zd3G3aX7lJIJ6KFOUQjDhd5NigSxiR1m1NF0zNjZ|IN88UU4> NIj5TGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
Sf21 cells NX\iUI5GTnWwY4Tpc44h[XO|YYm= MXrJcohq[mm2aX;uJI9nKG2xdYPlJJJm[2:vYnnuZY51KFCLM1vhcJBp[SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMucW6oZXP0[YQhW2Z{MTDj[YxteyxiSVO1NF0xNjVizszNMi=> MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2OEK2PUc,OTl5NEiyOlk9N2F-
Sf9 cells NFPaVFdndHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[Xl? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IHL5JIZtfW:{ZYPj[Y51KHCxbHHybZpifGmxbjDhd5NigQ>? NFjjVIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUGyNVY{OSd-MkGxNlE3OzF:L3G+
Sf9 cells NIHYc2dHdHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[Xl? NULUb2FrUW6qaXLpeIlwdiCxZjDoeY1idiCSSUPLZYxxcGFiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{BjgSCobIXvdoV{[2WwdDDwc4xiemm8YYTpc44h[XO|YYmsJGlEPTB;MD61OUDPxE1w MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF{MU[zNUc,OjFzMkG2N|E9N2F-
human IGROV1 cells M1rscWZ2dmO2aX;uJIF{e2G7 MVSyOEBp MnjrR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gTWdTV1ZzIHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCJMTDwbIF{\SCjdDC1JIZwdGRiSVO1NEBi\nSncjCyOEBpenNiYomg[oxwfyCleYTvcYV1enl? MkS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MU[xOVEoRjJzMkG2NVUyRC:jPh?=
human IGROV1 cells NEnsemxHfW6ldHnvckBie3OjeR?= NVHCW5dSOjRiaB?= MYnD[YxtKGO7Y3zlJIFzemW|dDDpckBpfW2jbjDJS3JQXjFiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNmKGG2IEGg[o9t\CCLQ{WwJIFnfGW{IEK0JIhzeyCkeTDmcI94KGO7dH;t[ZRzgQ>? NEH2bmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKxOlE2OSd-MkGyNVYyPTF:L3G+
human IGROV1 cells MU\GeY5kfGmxbjDhd5NigQ>? NX7wTXFtOjRxNEigbC=> M2XzXmlvcGmkaYTpc44hd2ZiUFmzT{9Cc3RiaX6gbJVu[W5iSVfSU3YyKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIHP5Z4xqdiCGMTDs[ZZmdCCjdDCxJJRwKDVidHnt[ZMhUUN3MDDh[pRmeiB{NDD0c{A1QCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NIrjXmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKxOlE2OSd-MkGyNVYyPTF:L3G+
human IGROV1 cells MkHXSpVv[3Srb36gZZN{[Xl? MnTRNlQwPDhiaB?= MlK3TY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDoeY1idiCLR2LPWlEh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHzleoVtKGG2IEGgeI8hPSC2aX3ld{BKSzVyIHHmeIVzKDJ2IITvJFQ5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MkDPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MU[xOVEoRjJzMkG2NVUyRC:jPh?=
human HCT116 cells MYjDfZRwfG:6aXRCpIF{e2G7 NGXETnc4OiCq NHXUb4REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF02Pi5yMTFOwG0v NFS0TVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm0OVI2OCd-MkG5OFUzPTB:L3G+
human KB cells NFu1[XNEgXSxdH;4bYPDqGG|c3H5 NW[1cWtiPzJiaB?= M{TT[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NESuO|Yh|ryPLh?= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2NUK1NEc,OjF7NEWyOVA9N2F-
HUVEC NETQZmpHfW6ldHnvckBie3OjeR?= Mo\aNVAuOjVizszN NFrxSZc{OCCvaX6= M32yb2lvcGmkaYTpc44hd2ZiVF7GZYxxcGFvc4TpcZVt[XSnZDDoeY1idiCLQ1HNMVEheHKxbX;0[ZIh[WO2aY\peJkh\XiycnXzd4VlKGmwIFjVWmVEKGG|c3Xzd4VlKGG|IHLleIEu\2GuYXP0c5Nq\GG|ZTDhZ5Rqfmm2eTDheEAyOCC2bzCyOUB2VSCycnX0doVifGWmIH\vdkA{OCCvaX7zJIJm\m:{ZTDUUmZidHCqYTDjbIFtdGWwZ3WgcYVie3W{ZXSgZYZ1\XJiNTDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5 NVLaNYVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwNlY1OTBpPkKyNFI3PDFyPD;hQi=>
HUVEC NYDQc2JrTnWwY4Tpc44h[XO|YYm= MX2xNE0zPSEQvF2= NUPjSWg6OTZiaB?= M2r0bWlvcGmkaYTpc44hd2ZiVF7GZYxxcGFvc4TpcZVt[XSnZDDJR2FONTFibWLORUBmgHC{ZYPzbY9vKGmwIFjVWmVEKGG2IEGwJJRwKDJ3IIXNJJBz\XS{ZXH0[YQh\m:{IEG2JIhzeyCkZX\vdoUhXE6IYXzwbIEh[2ijbHzlcodmKG2nYYP1doVlKGGodHXyJFYhcHK|IHL5JHJVNVCFUjDhcoFtgXOrcx?= NUnQTpdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwNlY1OTBpPkKyNFI3PDFyPD;hQi=>
human HCT116 cells NHu3cGJHfW6ldHnvckBie3OjeR?= NYrDPFMzOTBizszN MormTY5pcWKrdHnvckBw\iCDa4Sg[ZhxemW|c3nvckBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYSgNVAhfU1iYomgbY1ufW6xYnzveEBidmGueYPpdy=> M13EdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO|IyLz5{MkKxNlczOTxxYU6=
human HCT116 cells NFHHNG9HfW6ldHnvckBie3OjeR?= M{[3WFExKM7:TR?= MoLCTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiSEGwOFdTKG23dHHueEBqdiCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDa4SgV4VzPDd|IIDoc5NxcG:{eXzheIlwdiCjdDCxNEB2VSCkeTDpcY12dm:kbH;0JIFv[Wy7c3nz MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human HCT116 cells MomySpVv[3Srb36gZZN{[Xl? NXWxUlhJOTBizszN M1vIR2lvcGmkaYTpc44hd2ZiUFmzT4FteGijIHnuJIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGFsfCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIF1KDFyIIXNJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human HCT116 cells M4\uO2Z2dmO2aX;uJIF{e2G7 NGXYTYYyOCEQvF2= NFnoUlUyOCCvaX6= MX;Jcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCKMUC0O3IhdXW2YX70JIlvKGi3bXHuJGhEXDFzNjDj[YxteyC3c3nu[{BcOzKSXVHUVEBifCBzMDD1UUBi\nSncjCxNEBucW6| NX7MdIhjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVI4OjFpPkKyNlEzPzJzPD;hQi=>
human HCT116 cells MYPGeY5kfGmxbjDhd5NigQ>? M4TRbVExKM7:TR?= M{DrSVExKG2rbh?= MnnvTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiaX6gbJVu[W5iSFPUNVE3KGOnbHzzJJV{cW6pIGuzNnBeSVSSIHH0JFExKHWPIHHmeIVzKDFyIH3pcpM> NVzm[I9KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVI4OjFpPkKyNlEzPzJzPD;hQi=>
human HCT116 cells M3Lp[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXG0PEBp MoPRS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJHBKO0ujbIDoZUBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPU[uO{DPxE1w M4nR[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO|IyLz5{MkKxNlczOTxxYU6=
human HCT116 cells NVfDd2lDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MknJOFghcA>? M1vvPWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVUvQCEQvF2u M{XIZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO|IyLz5{MkKxNlczOTxxYU6=
human HCT116 cells NFPqTXFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmHZOFghcA>? NYHOT5BXT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy|IH;2[ZJmgHC{ZYPzbY5oKFCLM1vhcJBp[SCKMUC0O3IhdXW2YX70JIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NT6zJO69VQ>? NHXjWW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human A549 cells M2ryWGN6fG:2b4jpZ:Kh[XO|YYm= NFy0VZY4OiCq NWqxfGhMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6 M3Gx[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEiwPFUyLz5{MkS4NFg2OTxxYU6=
human PC3 cells NYTSUWZWS3m2b4TvfIlkyqCjc4PhfS=> MVO3NkBp MlzoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NkGuN|Uh|ryPLh?= NWfacHI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PFA5PTFpPkKyOFgxQDVzPD;hQi=>
human HL60 cells NIGxZY9EgXSxdH;4bYPDqGG|c3H5 MkDjO|IhcA>? MlHRR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUmuPVQh|ryPLh?= M3;wXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEiwPFUyLz5{MkS4NFg2OTxxYU6=
Sf21 cells M{juUmZ2dmO2aX;uJIF{e2G7 NVP6NIpzUW6qaXLpeIlwdiCxZjDtc5V{\SC5aXzkJJR6eGViUFmzT4FteGijIHX4dJJme3OnZDDpckBU\jJzIHPlcIx{KGOxLXX4dJJme3OrbnegUk11\XKvaX7hcEBJcXNvdHHn[4VlKGi3bXHuJJA5PWFidYPpcochVC2jbIDoZU1xcG:|cHjheIllgWyrbn;zbZRwdCC|dXLzeJJifGViYomgWGxEKGKjc3XkJJBpd3OyaH;yJIlu[WerbnesJGlEPTB;MD61JO69VQ>? NVHsV3dkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1NlA3OzBpPkKyOVIxPjNyPD;hQi=>
HEK293 cells NVnXPIJzTnWwY4Tpc44h[XO|YYm= NFTMfHIyNjViaB?= MWTEbZNxdGGlZX3lcpQhd2ZiW{PIYWxUTCCocn;tJIh2dWGwIEXIWFYhemWlZYD0c5Ih\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{Bi\nSncjCxMlUhcHK|IHL5JIxqeXWrZDDzZ4lvfGmubHH0bY9vKGOxdX70bY5o NUfyRZF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1N|cyPTNpPkKyOVM4OTV|PD;hQi=>
human H1299 cells NFrac|NHfW6ldHnvckBie3OjeR?= MWKwMlEuOzBizszN NXSwNJlIOjRiaB?= NVLCcZptUW6mdXP0bY9vKG:oIFrOT{1u\WSrYYTl[EBEUE:SIHX4dJJme3Orb36gbY4hcHWvYX6gTFEzQTliY3XscJMh[XRiMD6xJJRwKDNyIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NXXnd5ZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NlIxPjlpPkKyOlIzODZ7PD;hQi=>
human H1299 cells NHHofWdHfW6ldHnvckBie3OjeR?= MXuwMlEuOzBizszN M3fFWFI1KGh? M1LrXGlv\HWldHnvckBw\iCGUkWg[ZhxemW|c3nvckBqdiCqdX3hckBJOTJ7OTDj[YxteyCjdDCwMlEhfG9iM{CgeW0h[W[2ZYKgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NYjSdVVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NlIxPjlpPkKyOlIzODZ7PD;hQi=>
human H1299 cells MUDGeY5kfGmxbjDhd5NigQ>? MWWwMlEuOzBizszN M{fwfVI1KGh? NHLIUYRFd3ewIILl[5Vt[XSrb36gc4Yh[0mDUEKg[ZhxemW|c3nvckBqdiCqdX3hckBJOTJ7OTDj[YxteyCjdDCwMlEhfG9iM{CgeW0h[W[2ZYKgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyCrbjDwdoV{\W6lZTDv[kAyODBidXevcYwhXFKDSVygZY5lKFCLM1ugbY5pcWKrdH;yJGx[Ojl2MECy MnLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MkKwOlkoRjJ{NkKyNFY6RC:jPh?=
human H1299 cells NYjicW1JTnWwY4Tpc44h[XO|YYm= MUewMlEuOzBizszN MkXrNlQhcA>? M3KzN2Rwf25icnXneYxifGmxbjDv[kBkUUGSMjDlfJBz\XO|aX;uJIlvKGi3bXHuJGgyOjl7IHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ{MkC2PUc,OjJ4MkKwOlk9N2F-
MDA-MB-231 cells M1u0emNmdGxiaX72ZZNqd25iYYPzZZk> NGTnZVEzPCCq M1rqWmlvcGmkaYTpc44hd2ZiZYDpeIhmdGmjbDDndo94fGhiZnHjeI9zNWmwZIXj[YQh[2WubDDtbYdz[XSrb36gc4YhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDwdoUucW6ldXLheIVlKG[xcjCyOEBpenNiYomgZ4VtdCCrbo\hd4lwdiCjc4PhfUwhUUN3ME2wMlM5KM7:TT6= M{\Ie|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEC0NVA5Lz5{MkiwOFExQDxxYU6=
human LNCAP cells M2HhWmZ2dmO2aX;uJIF{e2G7 MmraNE4yNTNyIN88US=> NWjndJBzOjRiaB?= NEnRPWxFd3ewcnXneYxifGmxbjDv[kB{fXK4aY\pckBmgHC{ZYPzbY9vKGmwIHj1cYFvKEyQQ1HQJINmdGy|IHH0JFAvOSC2bzCzNEB2VSCjZoTldkAzPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh|MkOxOkc,OjJ6M{KzNVY9N2F-
human LNCAP cells M{LTXGZ2dmO2aX;uJIF{e2G7 M2\yb|AvOS1|MDFOwG0> NIHLOJE{OCCvaX6= NIHKVYhKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gUG5ESVBiY3XscJMh[XRiMD6xJJRwKDNyIIXNJIFnfGW{IEOwJI1qdnNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh|MkOxOkc,OjJ6M{KzNVY9N2F-
human PC3 cells MnLqSpVv[3Srb36gZZN{[Xl? MlnoOVAh|ryP MmjNPEBp NHf1NndKdmS3Y4Tpc44hd2ZicEKxJJBzd3SnaX6g[ZhxemW|c3nvckBqdiCqdX3hckBRSzNiY3XscJMh[XRiNUCgeW0hcW6ldXLheIVlKG[xcjC4JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIILlcIF1cX[nIITvJJVvfHKnYYTl[EBkd262cn;s NEHCUYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm5PFQ4Oid-MkK5PVg1PzJ:L3G+
human BT474 cell NXfIZ|FFWHKxbHnm[ZJifGmxbjDhd5NigQ>? NV;QT2xJPzJiaB?= NUDBZ3RMUW6qaXLpeIlwdiCxZjDoeY1idiCEVES3OEBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO|IhcHK|IHL5JJNx\WO2cn;wbI91d22ndILpZ{BidmGueYPpd-+9lCCLQ{WwQVIxNjdizszNMi=> NFvlboY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxNFAxPSd-MkO0NVAxODV:L3G+
human PC3 cell MmDuVJJwdGmoZYLheIlwdiCjc4PhfS=> MmHzO|IhcA>? M1TKWWlvcGmkaYTpc44hd2ZiaIXtZY4hWEN|IHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nlic4DlZ5Rzd3Cqb4TvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTF{LkGg{txONg>? MkmxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUCwNFUoRjJ|NEGwNFA2RC:jPh?=
human PC3 cells NHLZdXJHfW6ldHnvckBie3OjeR?= M1;BV|MxKG2rbh?= MYDJcohq[mm2aX;uJI9nKFCLM1ugbY4hcHWvYX6gVGM{KGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIFHLWEBxcG:|cHjvdplt[XSrb36gZZQhe2W{aX7lJFQ4OyCjZoTldkA{OCCvaX7zJIJ6KEWOSWPBMEBKSzVyPUGuN:69VS5? MmK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUCwNFUoRjJ|NEGwNFA2RC:jPh?=
human MGC803 cells NYDPS3VMTnWwY4Tpc44h[XO|YYm= MVqyOUDPxE1? MV:0PEBp M4HR[GNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJG1ISzhyMzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG|ZTDheEAzPSC3TTDh[pRmeiB2ODDodpMhfXOrbnegdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDh[pRmeiB2ODDodpMh[nliZnzve{BkgXSxbXX0[ZIhemWuYYTpeoUhfG9iY3;ueJJwdA>? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDFzOUi2PUc,OjRzMUm4Olk9N2F-
mouse RAW264.7 cells MkTlSpVv[3Srb36gZZN{[Xl? M2PrNlI2KM7:TR?= NITJXoczOCCq M1vyUGlvcGmkaYTpc44hd2ZiUFmzT{9CU1RiaX6gcY92e2ViUlHXNlY1NjdiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBNWFNvaX7keYNm\CCrTl;TJJBzd3SnaX6g[ZhxemW|c3nvckBifCB{NTFOwG0h[W[2ZYKgNlAhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? MlOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUm2NVYoRjJ2Mkm5OlE3RC:jPh?=
human A549 cells MWfQdo9tcW[ncnH0bY9vKGG|c3H5 MkH0O|IhcA>? M3z5UGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD16Mj6zNkDPxE1w MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ7M{e4O{c,OjV4OUO3PFc9N2F-
human HuH7 cells MnrRVJJwdGmoZYLheIlwdiCjc4PhfS=> NVLBXnk2PzJiaB?= MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEi3SEegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCjYoPvdoJidmOnIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PjdwMUig{txONg>? M1LmUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkmzO|g4Lz5{NU[5N|c5PzxxYU6=
human HCT116 cells NEHoRndRem:uaX\ldoF1cW:wIHHzd4F6 MknKO|IhcA>? NEDDWHBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIFje2:{YnHuZ4Uh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21NU45OiEQvF2u MmrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OUO3PFcoRjJ3NkmzO|g4RC:jPh?=
human HL60 cells MmXIVJJwdGmoZYLheIlwdiCjc4PhfS=> NI\CXow4OiCq NUnWS|lRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZYJ{d3KkYX7j[UBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUG4MlQ{KM7:TT6= M4D1elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkmzO|g4Lz5{NU[5N|c5PzxxYU6=
Sf9 cells NX3xTFg{TnWwY4Tpc44h[XO|YYm= NGGwcHdKdmirYnn0bY9vKG:oIFjpd{11[WepZXSgbJVu[W5iQ1uyJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNuIFnDOVAhRSB4Lkmg{txONg>? M4nxZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyOUm4N|UyLz5zMEm5PFM2OTxxYU6=
HeLa cells M2DLR2Z2dmO2aX;uJIF{e2G7 MmjQTY4hfmm2cn:gbY5pcWKrdHnvckBw\iCGTlGt[IVx\W6mZX70JJBzd3SnaX6gb4lv[XOnKFTORU1RUyliZoLvcUBJ\UyjIDjoeY1idiClYYLjbY5wdWFrIHPlcIx{NixiSVO1NEA:KDFwNDFOwG0v M{Xxc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{OUSxN|M6Lz5zMkm0NVM{QTxxYU6=
HeLa cells NXnse4l3TnWwY4Tpc44h[XO|YYm= MW\Jcohq[mm2aX;uJI9nKESQQTDk[ZBmdmSnboSgdJJwfGWrbjDrbY5ie2ViaYPvcIF1\WRiZoLvcUBJ\UyjIHPlcIx{NCCLQ{WwJF0hOS53IN88UU4> MlnpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4NUi4O|AoRjF3NkW4PFcxRC:jPh?=
Sf21 cells MYLGeY5kfGmxbjDhd5NigQ>? NHnKR4VKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2tj\XSjIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCVZkKxJINmdGy|LDDJR|UxKD1iMD65JO69VS5? M{X4e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{S4NlY6Lz5zOUe0PFI3QTxxYU6=
Sf21 cells NIe3PGdHfW6ldHnvckBie3OjeR?= MojKTY5pcWKrdHnvckBw\iCkb4\pcoUhemWlb33ibY5idnRiUFmzT4didW2jIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCVZkKxJINmdGy|LDDJR|UxKD1iNzFOwG0v NYrPeo0{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFgzPjlpPkG5O|Q5OjZ7PD;hQi=>
HeLa cells MoPQSpVv[3Srb36gZZN{[Xl? NHzFeWdC[3Srdnn0fUBifCCSSUPLJIlvKGi3bXHuJGhmVGFiY3XscJMh[nliRVzJV2EtKEWFNUCgQUAyNjVizszNMi=> M4q4eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMEmyN|I{Lz5{MEC5NlMzOzxxYU6=
Sf21 cells MU\GeY5kfGmxbjDhd5NigQ>? MoHMTY5pcWKrdHnvckBw\iCSSUPL[IVtfGFiZYjwdoV{e2WmIHnuJINmdGy|IHPvMYV5eHKnc4PpcochVi22ZYLtbY5idCCKaYOteIFo\2WmIHj1cYFvKHB6NXGgeZNqdmdiTD3hcJBp[S2yaH;zdIhifGmmeXzpco9{cXSxbDDzeYJ{fHKjdHWgZpkhXEyFIHLhd4VlKHCqb4PwbI9zKGmvYXfpcoctKEmFNUCgQUAxNjV5IN88UU4> M4HPc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUKwOlMxLz5{MkWyNFY{ODxxYU6=
Sf21 cells Mn7USpVv[3Srb36gZZN{[Xl? MkewTY5pcWKrdHnvckBw\iCqdX3hckB4cWymIIT5dIUhWEl|S3LleIEh\XiycnXzd4VlKGmwIGPmNlEh[2WubIOgZ48u\XiycnXzd4lv\yCQLYTldo1qdmGuIFjpd{11[WepZXSgbJVu[W5icEi1ZUB2e2mwZzDMMYFteGijLYDoc5NxcGG2aXT5cIlvd3OrdH;sJJN2[nO2cnH0[UBjgSCWTFOgZoF{\WRicHjvd5Bpd3JiaX3h[4lv\yxiSVO1NEA:KDBwOUeg{txONg>? NIW3ZWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWyNFY{OCd-MkK1NlA3OzB:L3G+
HL60 cells NXK2S5dRSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M2TsSFMh\GG7cx?= MlTqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IH3lZZN2emWmIHHmeIVzKDNiZHH5d{BjgSCPVGOgZZN{[XluIFnDOVAhRSBzNDFOwG0v M2n1WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUS1NVExLz5{Nkm0OVEyODxxYU6=
U937 cells MlzqRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MVizJIRigXN? M1rVdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUmzO{Bk\WyuczDt[YF{fXKnZDDh[pRmeiB|IHThfZMh[nliTWTTJIF{e2G7LDDJR|UxKD1iMUSg{txONg>? M4nl[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUS1NVExLz5{Nkm0OVEyODxxYU6=
Jurkat cells NH\uT5BCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MYezJIRigXN? NH71RVJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFr1dotifCClZXzsd{Bu\WG|dYLl[EBi\nSncjCzJIRigXNiYomgUXRUKGG|c3H5MEBKSzVyIE2gNlIh|ryPLh?= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl2NUGxNEc,OjZ7NEWxNVA9N2F-
K562 cells M2rQ[WFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NY\PXZFqOyCmYYnz NWDkToFkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJI1m[XO3cnXkJIFnfGW{IEOg[IF6eyCkeTDNWHMh[XO|YYmsJGlEPTBiPTCzPEDPxE1w NFnzN2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm0OVEyOCd-Mk[5OFUyOTB:L3G+
U266 cells MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NWizTFhSOyCmYYnz NUTWfFd5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVNlY3KGOnbHzzJI1m[XO3cnXkJIFnfGW{IEOg[IF6eyCkeTDNWHMh[XO|YYmsJGlEPTBiPTC0OkDPxE1w NFO1OlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm0OVEyOCd-Mk[5OFUyOTB:L3G+
MDA-MB-231 cells MYXBcpRqdWmpcnH0c5J6KGG|c3H5 MXKyOEBpenN? MUDBcpRqdWmpcnH0c5J6KGGldHn2bZR6KGGpYXnud5QhTUeIIHnu[JVk\WRiY3jlcY91[XirczDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IIDy[Ylv[3WkYYTl[EBnd3JiMkSgbJJ{KG[xbHzve4VlKGK7IFXHSkBi\GSrdHnvckBnd3JiMz61JIhzeyCkeTDsbYdpfCCvaXPyc5Nkd3C7LDDJR|UxKD1iMD6zPEDPxE1w NFrSRVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W5PFI{Pyd-Mke1PVgzOzd:L3G+
MDA-MB-231 cells M2DSVGFvfGmrbo\hd4l3\SCjc4PhfS=> MlPNN{42KGi{cx?= M1vlVGFvfGmrbo\hd4l3\SCjY4Tpeol1gSCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhTUeILXnu[JVk\WRiY3XscEBqdn[jc3nvckBi\nSncjCzMlUhcHK|LDDJR|UxKD1iMD6zPEDPxE1w NVnEfIhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwNFk2OjFpPkK4NFA6PTJzPD;hQi=>
HEK293T cells M4j2SGZ2dmO2aX;uJIF{e2G7 M4W3WVEhcHJ? MYnJcohq[mm2aX;uJI9nKGmvbX;ibYxqgmWmIF6tUHkzQTRyMEKgZoVi\CCkaX7kbY5oKHSxIGDJN2tj\XSjIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGhGUzJ7M2SgZ4VtdHNiaX7jeYJifGWmIH\vdkAyKGi{IHL5JGxENU2VL13TJIFv[Wy7c3nzMEBKSzVyIE2gNE41OiEQvF2u MlfxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OECyOlEoRjJ6MkiwNlYyRC:jPh?=
HEK293T cells MniwSpVv[3Srb36gZZN{[Xl? MnPPNUBpeg>? M33ISGlvcGmkaYTpc44hd2ZiaX3tc4JqdGm8ZXSgUk1NYTJ7NECwNkBj\WGmIHLpcoRqdmdidH:gVGk{U2SnbIThJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKEiHS{K5N3Qh[2WubIOgbY5kfWKjdHXkJIZweiBzIHjyJIJ6KEyFLV3TM21UKGGwYXz5d4l{NCCLQ{WwJF0hOS53MzFOwG0v MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MEK2NUc,Ojh{OECyOlE9N2F-
HEK293T cells NIq1[3ZHfW6ldHnvckBie3OjeR?= MVexJIhz Mn\HTY5pcWKrdHnvckBw\iCrbX3vZoltcXqnZDDOMWx[Ojl2MECyJIJm[WRiYnnu[Ilv\yC2bzDQTVNM[WyyaHGgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hUEWNMkmzWEBk\WyuczDpcoN2[mG2ZXSg[o9zKDFiaIKgZpkhVENvTWOvUXMh[W6jbInzbZMtKEmFNUCgQUAzNjN5IN88UU4> NEPvU5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
MDA-MB-231 cells MYjGeY5kfGmxbjDhd5NigQ>? NHHHO25KdmirYnn0bY9vKG:oIFXHSk1qdmS3Y3XkJIlvfmG|aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5|ODFOwG0v MoToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MEK0NFEoRjJ6M{CyOFAyRC:jPh?=
MCF7 cells NEjkbY1HfW6ldHnvckBie3OjeR?= NYS0XnZ3OTBidV2= MlPFNUBpeg>? MYDJcohq[mm2aX;uJI9nKEmJRkHSJJBpd3OyaH;yfYxifGmxbjDheEBVgXJzMU[xJJJme2mmdXWgbY4hcHWvYX6gUWNHPyClZXzsd{BifCBzMDD1UUBi\nSncjCxJIhzKGK7IFjv[YNpe3RiM{OyOVghe3SjaX7pcoch[mG|ZXSgbY1ufW6xaHnzeI9kcGWvaXPhcEBidmGueYPpdy=> M4\5RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUW3OFMxLz5{OEW1O|Q{ODxxYU6=
SKOV3 cells MUPGeY5kfGmxbjDhd5NigQ>? MkjTNlAhfU1? MV2yOEBpenN? M{[5Z2lvcGmkaYTpc44hd2ZiQlTOSk1qdmS3Y3XkJIlvfmG|aX;uJIlvKGi3bXHuJHNMV1Z|IHPlcIx{KGG2IEKwJJVOKGGodHXyJFI1KGi{czDpckBjgSCvYYTybYdmdCCrbo\hd4lwdiCjc4PhfS=> NYX4O25PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxNlI1QDRpPkK5NVIzPDh2PD;hQi=>
SKOV3 cells MmHPRY51cW2rZ4LheI9zgSCjc4PhfS=> MWmyNEB2VQ>? NU\VOVlmOjRiaILz NIfBVmxCdnSrbXnndoF1d3K7IHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCERF7GMYlv\HWlZXSgZ4VtdCCvaXfyZZRqd25iYYSgNlAhfU1iYX\0[ZIhOjRiaILzJIJ6KHOlcnH0Z4ghf2:3bnSgbIVidGmwZzDhd5NigQ>? M3nYUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUKyOFg1Lz5{OUGyNlQ5PDxxYU6=
NB1643 cells MlvvdWhVWyCjc4PhfS=> MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 cells NULVbphveUiWUzDhd5NigQ>? NUnJPY1peUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> NEi0e5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 cells NYOwSJhVeUiWUzDhd5NigQ>? MnXVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= NHTQe|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC cells MWLxTHRUKGG|c3H5 NIi5fXNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NFPreXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
J774 cells NVfLOXVSSW62aXnu[oxidW2jdH;yfUBie3OjeR?= M2\vN|I1KGi{cx?= NXLHZ29GSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBLPzd2IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBNWFNvaX7keYNm\CCPQ2CxJIV5eHKnc4Ppc44h[W[2ZYKgNlQhcHK|IHL5JGVNUVODLDDJR|UxKD1iMz63JO69VS5? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd{Nk[4NEc,Ojl5Mk[2PFA9N2F-
J774 cells M2P5fWFvfGmrbn\sZY1u[XSxcomgZZN{[Xl? MX6yOEBpenN? M2O3e2FvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgTlc4PCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gUHBUNWmwZIXj[YQhUUx4IHX4dJJme3Orb36gZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwJF0hPS5zIN88UU4> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd{Nk[4NEc,Ojl5Mk[2PFA9N2F-
J774 cells NHKxNHJCdnSraX7mcIFudWG2b4L5JIF{e2G7 NXrtXGFmOjRiaILz M{LOfmFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgTlc4PCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gUHBUNWmwZIXj[YQhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36gZYZ1\XJiMkSgbJJ{KGK7IFfybYV{eyCjc4PhfUwhUUN3MDC9JFgvQSEQvF2u M1GwOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{K2OlgxLz5{OUeyOlY5ODxxYU6=
J774 cells NWCzWXRETnWwY4Tpc44h[XO|YYm= Mo\JNVAhfU1? M4fJWFQhcHK| NIPjTZZKdmirYnn0bY9vKG:oIGDJN2swSWu2IHnuJI1wfXOnIFq3O|Qh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIFzQV{1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44h[XRiU3XyOFc{KGG2IEGwJJVOKGGodHXyJFQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? M3fEb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{K2OlgxLz5{OUeyOlY5ODxxYU6=
Assay
Methods Test Index PMID
Western blot E-cadherin / p-Akt / Akt ; beta-catenin / p-GSK3β / Cyclin D1 ; Bcl-xl / Bax / caspase3 / cleaved caspase-3 ; p-p70S6K (T389) / p-GSK3β(S9) / pERK / Vinculin ; pPKB-S473 29731993 25344912 23251002 20649566
Growth inhibition assay Cell viability 25344912
Immunofluorescence α-SMA / CD31 ; E-cadherin / beta-catenin ; COX-2 / p-NFκB ; FOXO3a 27671604 29731993 18388194
ELISA IL-10 / IL-1β / TNFα / IL-6 22208359
In vivo

LY294002 also results in suppression of tumor growth and induction of apoptosis, especially in the LoVo tumors, and therefore shows remarkable effectiveness in the mouse peritonitis carcinomatosa model. [2] LY294002 significantly inhibits growth and ascites formation of ovarian carcinoma. [3]

Protocol (from reference)

Kinase Assay:

[4]

  • kinase assays:

    PI3K inhibition by LY294002 is determined in a radiometric assay using purified, recombinant enzymes with 1 μM ATP. The kinase reaction is carried out for 1 hour at room temperature (24oC) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose–response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. LY294002 is tested against the Upstate panel of kinases in 10 μM ATP.

Cell Research:

[2]

  • Cell lines: Colon cancer cell lines DLD-1, LoVo, HCT15, and Colo205
  • Concentrations: 0–50 μM
  • Incubation Time: 0–48 hours
  • Method:

    1.0×105 cells (100 μL volume/well) are inoculated into 96-well microtiter plates. LY294002 is added to triplicate wells and cultured at 37oC for 0–48 hours. After treatment, 10 μL of Premix WST-1 are added to each microculture well, and the plates are incubated for 60 minutes at 37oC, after which absorbance at 450 nm is measured with a microplate reader.

Animal Research:

[3]

  • Animal Models: Two groups of athymic nude mice (5–7 weeks) are inoculated i.p. with OVCAR-3 cells
  • Dosages: 0–100 mg/kg
  • Administration: Administered via i.p.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+ 40%PEG 300+5% Tween 80+50%ddH2O
For best results, use promptly after mixing.

3mg/mL

Chemical Information

Molecular Weight 307.34
Formula

C19H17NO3

CAS No. 154447-36-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02337309 Terminated Drug: SF1126 Neuroblastoma New Approaches to Neuroblastoma Therapy Consortium|SignalRX Pharmaceuticals Inc.|University of Southern California July 9 2015 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
I want to buy a inhibitor that can inactivates Akt/PI3K. I notice the protocol of LY294002 (catalog no. s1105) says it will inactivates Akt/PKB. Is LY294002 available for Akt/PI3K inhibition?

Answer:
LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively. It can inhibit PI3K/AKT. PKB is the alternative name of AKT.

Question 2:
What is the suggested formulation of this compound for mouse injection(i.p.)?

Answer:
It can be dissolved in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml clearly, and the concentration of DMSO is safe for in vivo experiments.

Tags: buy LY294002 | LY294002 supplier | purchase LY294002 | LY294002 cost | LY294002 manufacturer | order LY294002 | LY294002 distributor